SYBLEU INC (SYBE)
USD 0.06
(34.15%)
USD 0.06
(34.15%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 160.87 Thousand USD | 136.33% |
| 2021 | 68.07 Thousand USD | -26.25% |
| 2020 | 92.3 Thousand USD | 99.33% |
| 2019 | 46.3 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q1 | 24.79 Thousand USD | 212.25% |
| 2023 Q3 | 134.99 Thousand USD | 19.72% |
| 2023 Q4 | 23.43 Thousand USD | -82.64% |
| 2023 Q2 | 112.75 Thousand USD | 354.8% |
| 2022 Q3 | 19.2 Thousand USD | 0.0% |
| 2022 FY | 160.87 Thousand USD | 136.33% |
| 2022 Q4 | 7940.00 USD | -58.67% |
| 2021 FY | 68.07 Thousand USD | -26.25% |
| 2020 FY | 92.3 Thousand USD | 99.33% |
| 2019 FY | 46.3 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 87.953% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 96.809% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 99.456% |
| Nascent Biotech, Inc. | 2.22 Million USD | 92.785% |
| Rebus Holdings, Inc. | 664 Thousand USD | 75.772% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 99.568% |
| Qrons Inc. | 643.67 Thousand USD | 75.007% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | 58.704% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 99.72% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 61.279% |
| Skye Bioscience, Inc. | 13.54 Million USD | 98.813% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.815% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 96.729% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | 38.533% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.812% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 94.483% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 89.288% |
| Mesoblast Limited | 5.9 Million USD | 97.274% |
| Marizyme, Inc. | 19.23 Million USD | 99.164% |
| Genus plc | 147.7 Million USD | 99.891% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 98.168% |
| Pharming Group N.V. | 225.49 Million USD | 99.929% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 92.147% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 88.008% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 98.071% |
| ContraFect Corporation | 56.88 Million USD | 99.717% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 96.351% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 89.121% |
| IMV Inc. | 37.7 Million USD | 99.573% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 94.235% |
| MultiCell Technologies, Inc. | 567.42 USD | -28252.191% |
| ONE Bio Corp. | 6.44 Million USD | 97.503% |
| Accustem Sciences Inc. | 3.74 Million USD | 95.706% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.813% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | 69.758% |
| Q BioMed Inc. | 3.43 Million USD | 95.319% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 99.349% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 93.877% |
| Biomind Labs Inc. | 994.18 Thousand USD | 83.818% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.838% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 90.858% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 97.605% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 91.371% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 743.504% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 98.995% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 91.233% |
| GB Sciences, Inc. | 1.42 Million USD | 88.675% |
| Alpha Cognition Inc. | 9.7 Million USD | 98.342% |
| HST Global, Inc. | 140.9 Thousand USD | -14.172% |
| CSL Limited | 3.44 Billion USD | 99.995% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 85.699% |
| Halberd Corporation | 74.84 Thousand USD | -114.954% |
| Enzolytics Inc. | 2.17 Million USD | 92.619% |
| Agentix Corp. | 1.37 Million USD | 88.272% |
| Resverlogix Corp. | 12.71 Million USD | 98.734% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 95.593% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.99% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 84.59% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 93.311% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 89.814% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 95.275% |
| AVAX Technologies, Inc. | 7.31 Million USD | 97.799% |
| Zenith Capital Corp. | 8.94 Million USD | 98.201% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.981% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -823.46% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 93.448% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | 6.2% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 91.625% |
| Kadimastem Ltd | 2.41 Million USD | 93.325% |
| Helix BioMedix, Inc. | 1.97 Million USD | 91.842% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 98.52% |
| BioStem Technologies, Inc. | 22.97 Million USD | 99.3% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | 11.356% |
| LadRx Corporation | 3.81 Million USD | 95.78% |
| Cell Source, Inc. | 4.32 Million USD | 96.281% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 82.58% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 82.58% |
| NovAccess Global Inc. | 2.46 Million USD | 93.478% |
| Affymax, Inc. | 39.38 Million USD | 99.592% |
| Itoco Inc. | 919.14 Thousand USD | 82.497% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 96.204% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 85.623% |
| Mobile Lads Corp. | 554.54 Thousand USD | 70.99% |
| CytoDyn Inc. | 18.05 Million USD | 99.109% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -539.183% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | 26.9% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 88.669% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 91.143% |
| International Stem Cell Corporation | 5.27 Million USD | 96.948% |
| Bioxytran, Inc. | 3.82 Million USD | 95.789% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -205.604% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -690.817% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 99.556% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 90.057% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 78.137% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 94.829% |
| Neutra Corp. | 243.82 Thousand USD | 34.019% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 99.078% |
| PureTech Health plc | 144.59 Million USD | 99.889% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 99.215% |
| IXICO plc | 4.7 Million USD | 96.582% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 98.171% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.863% |
| CSL Limited | 3.89 Billion USD | 99.996% |
| Cellectis S.A. | 97.32 Million USD | 99.835% |